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Increasing the volumetric titer of recombinant therapeutic proteins is a key 
objective in bioprocess manufacturing development.  Carboxylic acids have demonstrated 
the ability to improve synthesis of recombinant proteins in industrially important cell 
lines such as Chinese Hamster Ovary (CHO) cells. The improvement in the production of 
recombinant proteins has been linked in a number of molecules to the inhibition of 
histone deacetylase, leading to increased transcription of genes.  However, carboxylic 
acids have been shown to promote an apoptotic response in CHO cell culture.  Pentanoic 
acid is a carboxylic acid that has demonstrated lower apoptotic response in culture 
relative to the carboxylic acid butanoic acid, while maintaining the ability to improve 
recombinant protein production. 
Supplementation of cultures with anti-oxidants has shown the ability to reduce the 
apoptotic response of butanoic acid supplementation leading to increased therapeutic 
protein production.  Here we show improved production with pentanoic acid and further 
  iv 
 
improvements combining induction with supplementation of the antioxidant n-acetyl 
cysteine (NAC). 
Pentanoic acid induction of CHO cell cultures was studied in time-course 
experiments looking at growth, productivity, and apoptosis.  Pentanoic acid was shown to 
reduce the number of cells entering early apoptosis relative to butanoic acid by 15.4%. 
The supplementation of butanoic acid and pentanoic acid treated cultures with n-acetyl 
cysteine reduced the population of cells entering early apoptosis by 5.3% and 10.0%, 
respectively. A 19.5% increase in productivity was observed in pentanoic acid treated 
cultures when supplemented with n-acetyl cysteine. This research provides evidence for a 
culture supplementation method that can be used in the optimization of 
biopharmaceutical manufacturing processes. 
(79 pages) 
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To improve the cost of producing protein therapeutics manufacturers can attempt 
to increase the amount of protein produced per unit volume.  Some small fatty-acids have 
shown the ability to increase protein concentrations in some manufacturing systems.  An 
example system is in the industrially important cell line derived from a Chinese Hamster 
Ovary (CHO).  A drawback of adding these fatty-acids is they can increase the rate of 
cell death. 
A potential way to minimize the cell death rate, caused by adding fatty-acids, is to 
also add additional anti-oxidants.  Through a series of studies, we demonstrate production 
with different fatty-acids, butanoic acid and pentanoic acid, with the addition of the 
antioxidant, n-Acetyl cysteine (NAC). 
vi 
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1.1 Background and Significance 
Biological pharmaceuticals play a significant role in human health care ranging 
from cancer therapy to the breakdown of blood clots during a heart attack.  These 
biopharmaceuticals drugs are principally produced by recombinant protein technologies, 
where gene sequences foreign to a biological host, are used to produce a non-native 
protein, in the host cell system.  The demand for biopharmaceuticals is large and is 
expected to continue to grow over the coming decades.  A large number of 
biopharmaceuticals rely on mammalian cells as a production vehicle with their ability to 
produce bioactive post-translationally modified glycoproteins. 
Manufacturing process optimization with a target of increasing the volumetric 
production of recombinant proteins can reduce cost and time of the manufacturing 
process.  A number of carboxylic acids have demonstrated the ability to improve 
synthesis of recombinant protein in industrially important cell lines such as Chinese 
Hamster Ovary (CHO) cells.   The increased productivity attributed to carboxylic acid 
has been attributed to the hyper-acylation of histones.  Histones are proteins that 
deoxyribonucleic acid (DNA) winds around to create chromatin structures in eukaryotic 
cell nuclei.  The hyperacetylation of the histone unwinds the DNA leaving it more readily 
available for transcription, leading to increased gene translation and productivity.  
Butanoic acid is a carboxylic acid that has been shown to block cell proliferation in the 
G1 cell cycle phase, this may also be a source of increased productivity in some cell lines 
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However, butanoic acid supplementation of cultures has been shown to promote 
an apoptotic response in CHO cell culture.  An alternative carboxylic acid, pentanoic 
acid, has been shown to enhance the volumetric productivity of recombinant proteins 
(Liu et al. 2001). 
Supplementation of cultures of cells with anti-oxidants has shown the ability to 
reduce the apoptotic response to carboxylic acid supplementation leading to increased 
therapeutic protein production.  Antioxidant addition to cultures can improve post-
treatment performance of cultures by minimizing apoptosis. 
With an optimization target of increasing recombinant protein production in CHO 
cell lines a screen of multiple carboxylic acids was performed.  Selected carboxylic acids 
were then screened with an antioxidant for further improvement of recombinant protein 
production.    
Here we show improved production with pentanoic acid and further 
improvements combining induction with supplementation of the antioxidant n-acetyl 
cysteine (NAC). 
1.2 Hypothesis 
Small molecules can enhance the level of heterologous recombinant protein 
production. However, it has been observed that treatment with small molecule enhancers 
can induce apoptosis in the cultures.  Antioxidants addition to these cultures can improve 
post-treatment performance of cultures by minimizing apoptosis. 
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1.3 Research Objectives 
As a screening tool, analyze the performance of components as single parameters 
to observe does response concentration curves.  Using a scale-down model 96 well 
microtiter plate culture system, gradients of test components will be analyzed over initial 
ranges of 0-20mM.  The objective is to determine response concentrations of test 
components. 
Design and analyze experiments looking at primary and secondary effects of 
combinations of selected small molecules and antioxidants.  Assuming that Small 
Molecule Enhancers improve volumetric productivity, but have a negative impact on 
growth kinetics and that antioxidants show neutral to improved productivity or growth 
kinetics a factorial design of experiment is proposed to explore the possibility of 
improved performance from antioxidant addition to Small Molecule Enhancer induced 
cultures. 
Explore the cause of reduced culture performance following induction with Small 
Molecule Enhancers and any positive effects from treatment with antioxidants.  
Apoptosis stimulation will be explored as an explanation for reduced culture growth 
performance after addition of Small Molecule Enhancers.  Assuming apoptosis explains 
reduced culture performance, the effect of addition of anti-oxidants on apoptosis will be 
explored. 
1.4 References 
Liu CH, Chu IM, Hwang SM. 2001. Pentanoic acid, a novel protein synthesis stimulant 
for Chinese hamster ovary (CHO) cells. Journal of Bioscience and Bioengineering 
91(1):71-75. 
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CHAPTER 2 
 LITERATURE REVIEW 
 
2.1 Biopharmaceuticals 
Over the last 35 years biopharmaceuticals have played an increasingly important 
role in human and animal health.   As opposed to traditional chemical pharmaceuticals, 
typified by small molecule drugs, biopharmaceuticals are biotechnology-derived.   
Biopharmaceuticals encompass a broad range of treatments for areas that include 
arthritis, enzyme replacement, allergy, cancer therapy, infertility, cardiology, 
inflammatory diseases, blood disease, myocardial infarction, cystic fibrosis, organ 
transplant, and tissue growth and repair.  Within the broad category of 
biopharmaceuticals are a variety of compounds and treatments; nucleic acids including 
gene therapies, vaccines, cell therapy, and therapeutic proteins.  Within therapeutic 
proteins are three main categories; recombinant proteins, monoclonal antibodies, and 
purified proteins.  An example of a recombinant protein is Octocog (Table 1), a blood 
enzyme known as Factor VIII.  It is used as an enzyme replacement therapy in the 
treatment of hemophilia A.  An example of a monoclonal antibodies is Adalimumab 
(Table 1) a recombinant human IgG1 that targets human tumor necrosis factor-alpha 
(TNF-alpha).  It is a glycosylated protein that contains 1,330 amino acids and has a 
molecular weight of about 148 kilodaltons (Vena and Cassano 2007).  Adalimumab is 
able to bind TNF-alpha, a naturally occurring cytokine involved in inflammatory and 
immune response (Arora 2007), thus blocking its ability to bind to the TNF-alpha cell 
surface receptors, p55 and p75. 
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Table 1  Select list of FDA approved biopharmaceuticals that have reached 
blockbuster status (>$1 billion) in sales.(Bioplan Associates 2013)  
 
In 2013 it was estimated that there were 435 biopharmaceuticals approved for use 
in the United States and Europe (Bioplan Associates 2013).  Of the approximately 10,000 
therapeutic in R&D, it is estimated that 40% are biopharmaceuticals.  In 2013 it was 
estimated that biopharmaceuticals had a market size of about $165 billion and was 
growing at a 15% compounding annual growth rate.  This market size represents 
approximately 15% of the estimated $1 trillion total pharmaceutical market.  It is 
estimated that the biopharmaceutical market will grow to greater than $210 billion by 
2015 (Technavio 2013).  The biopharmaceutical industry group, PhRMA, estimated that 
in 2012 there was $48.5 billion spent on research and product development innovations 
(PhRMA 2013).   It is projected that this funding trend will continue with the potential 
for nearly 50% of pharmaceutical R&D projected to be devoted to biopharmaceuticals 
(Bioplan Associates 2013). 
Name Product Class Cell Line 
Adalimumab TNF MAb Monoclonal Antibody CHO 
Bevacizumab VEGF MAb Monoclonal Antibody CHO 
Epoetin alfa EPO Recombinant Protein CHO 





Infliximab TNF MAb Monoclonal Antibody SP2/0 
Insulin Glargine Insulin Glargine Recombinant Protein Escherichia coli 
Octocog Factor VIII Recombinant Protein CHO 
Pegfilgrastim G-CSF Pegylated Recombinant Protein Escherichia coli 
Ranibizumab VEGF MAb Fab Monoclonal Antibody 
Fragment 
Escherichia coli 
Rituximab CD20 MAb Monoclonal Antibody CHO 
Trastuzumab HER2 Receptor 
MAb 
Monoclonal Antibody CHO 
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2.2 Monoclonal Antibodies  
Within biopharmaceuticals, monoclonal antibodies are an important segment.  
Seven of the top ten selling biopharmaceuticals in 2011 were monoclonal antibodies or 
fragments of monoclonal antibodies.  Monoclonal antibodies are natural occurring 
glycosylated proteins that play a major role in the body’s immune system.  They are 
monospecific to an antigen and are produced by B lymphocytes, a class of immune cells, 
in response to an antigen.  Specific B lymphocyte only produces one specific antibody 
and have limited, to no proliferation capacity.  In 1975, George Kohler and Cesar 
Milstein demonstrated that a specific B cell could be isolated and fused with a cancerous 
myeloma cell line.  The B cell bringing the ability to produce a specific antibody and the 
myeloma cell conferring the ability to replicate rapidly and indefinitely.  This process, 
known as hybridoma technology, ushered in a process to allow expanded production of a 
monoclonal antibody to a specific target molecule.  One method for producing the B cell 
needed for the fusion is to expose a mouse to an antigen in two phases, a priming dose 
and a booster dose.  Following treatment with the antigen a sample of the spleen can be 
harvested.  Following fusion with the myeloma cell line the hybridoma population can be 
screened for a population producing the antibody of interest. 
Immune recognition and response in humans to IgG produced in other species 
prompted the move to more human-like IgG.  Most therapeutics antibodies are either 
humanized or are fully human IgG and are produced as recombinant glycoproteins in 
mammalian cells (Beck et al. 2008).  Humanized monoclonal antibodies are genetic 
constructs that contain both human and non-human gene sequences for specific antibody 
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regions, the conserved genetic regions coming from human sequences and the variable 
genetic sequences, specific to an antigen, regions coming from species donating the B-
cell Lymphocyte.   
MAb are generally expensive therapies that can cost more than $100,000 per year 
or over the course of full treatment (Bioplan Associates 2013).  The high cost of MAb 
treatment can be attributed to low potency and short half-life, requiring large and frequent 
dosages.  These factors lead to large amounts of MAb being needed to treat patient 
populations.  It is estimated that around 90% of the world-wide production capacity for 
mammalian cell culture is for MAb production (Bioplan Associates 2013).  Much of this 
production requires the use of large volume bioreactors at the 10,000 L scale. 
2.3 Recombinant DNA Technology 
With the introduction of recombinant protein production in 1974 by Herbert 
Boyer at University of California San Francisco and Stanley Cohen at Stanford it was 
possible to engineer systems for the manufacturing of biopharmaceuticals, rather than 
purification of proteins from source tissue and organs.  Recombinant proteins and 
glycoproteins are the products of exogenous gene sequences.  These recombinant genes 
can be spliced into the genome of alternative cells to be used as a production system.   
The alternative cell line systems provide the gene replication, transcription, translation, 
and if required the secretion of the targeted proteins and glycoproteins.  Recombinant 
gene expression cassettes typically contain promoters, initiation sequences and may 
contain introns and exons, and coding sequences such as polyadenylation signals. 
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The predominant production system for biopharmaceuticals use recombinant 
DNA technology.  Early recombinant engineered systems relied on proteins produced in 
bacterial systems.  E. coli are an example of a bacterial production system used to 
produce recombinant proteins that lack typical mammalian post-translational 
modifications.  When complex, human-like post-translational modifications are needed 
then mammalian cells are the typical system used for biopharmaceutical production.  The 
primary post-translational modification is protein glycosylation, a modification where 
polymers of sugars are attached to proteins.  
These drugs have played an important role in human health care over the last 30 
years (Brown 2005; Carter 2011).   A typical development process for production using 
recombinant DNA would start with identification of a target gene sequence (Figure 1).  
An expression cassette may be developed then used in a transient expression system.  
Transient expression systems rely on introduction of the recombinant DNA into the cell 
line, but the gene isn’t incorporated in the cell genome.  However, using the native 
cellular processes the gene of interested is transcribed and then the target proteins in 
translated from the transcribed mRNA.  The resulting recombinant protein can then be 
tested for bioactivity and toxicity.  Transient production systems are typically low-level 
production systems, thus requiring the production of stable cell line for optimized protein 
expression.  Selected genes are then used to produce stable cell lines that have the gene 
incorporated into the production cell line genome.   
Within biopharmaceutical production, Chinese Hamster Ovary cells are one of the 
predominate cell systems used, because of relatively straightforward genetic 
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manipulation of the cell line, growth of the cell line is rapid and can be optimized, and 
general acceptance of use of this cell line by government regulatory bodies such as the 
FDA and EMEA. 
 
 
Figure 1  Flow diagram of development of a recombinant production cell line.   
 
Recombinant cell lines used for production are generally screened in a clonal 
selection process, to eliminate non-producers and select clones with higher production 
rates.  Chosen clones can then be optimized in scale-down model systems of full large-
scale production processes.  
2.4 Production of Biopharmaceuticals. 
The production of human therapeutics that require unique processing to be active, 
relies on mammalian cells because of their ability to correctly fold, perform post-
translational modifications, and secrete proteins that aren’t possible in microbial and 
plant-based systems.  (Omasa et al. 2010a) 
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Mammalian cell culture can be traced back to organ culturing techniques in the 
19th century.  By the 1950’s many procedures had been developed for culturing cells 
outside of mammalian cells.  Of main importance in advancing the process, at this time, 
were studies in the production of virus.  To facilitate growth in vitro culture conditions 
were created similar to the environment in vivo, with serum being a primary constituent 
in most culturing systems.  Serum being an animal-blood product provided many 
important factors, including, metabolites, growth factors, mitogens, lipids, and proteins.  
To minimize the use of serum, a costly and variable component, basal liquid formulations 
consisting of carbohydrates, to supply energy, amino acids, vitamins and salts were 
developed.  Although an undefined supplement, serum played an important role in 
culturing, supplying growth factors, lipid carriers, antioxidants, protease inhibitors, 
however, its undefined character could lead to variability in performance.  Its collection 
from abattoirs as a byproduct of the beef industry made it subject to variability in supply 
with the result that as a commodity it price could fluctuate dramatically.  The 
development of basal media formulations allowed for serum to be reduced to levels of 5-
15% of culture volume and in some cases to be eliminated altogether.  When 
biopharmaceutical production started to develop and grow in the 1970’s and 1980’s, 
serum was still an important culture supplement for production.  By the 1990’s 
formulations and culturing methods were beginning to be introduced for protein 
production without the use of serum.   Because of product life cycles, cost to develop new 
processes and systems, there are many legacy products that are still manufactured using 
serum.   
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Along with advancements in culture media formulations, systems for 
manufacturing have advanced over the last three decades.  Processes for 
biopharmaceutical production include batch, fed-batch, and perfusion or variations of 
these systems.  Some manufacturing processes rely on batch methods for their simplicity, 
although most processes are currently fed-batch processes.  This manufacturing method 
lends itself well to serum-free formulation advancements in the last two decades, since 
known depleted components could be fed into the process during culture processes.  
Although perfusion-based systems of production have been developed, views that they 
are complex have limited their use.  However, current pushes in development are 
focusing on perfusion as ideal manufacturing system of future production platforms. 
After identification of the product of interest and production cell line generation, 
the next step is production of a Master Cell Bank.  A production process (Figure 2) would 
then start with a Working Cell Bank being produced.  Typically, cell banks consist of 
small volume aliquots of cells preserved in cryostorage, in volumes in the 0.5 to 10mL 
range.   
 
Figure 2  Bioprocess Schematic showing seed train procession. 
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Production of biopharmaceuticals in mammalian cell lines remains an expensive 
and complex process.  Increasing the volumetric titer of recombinant therapeutic proteins 
is a key objective in bioprocess manufacturing development.  To achieve higher product 
titers, driving down cost, researchers have employed multiple strategies.  A typical 
process will use suspension cells (Figure 2), were cells grow detached from contact 
surfaces. Processes over the last 20 years have increasingly been engineered to use 
serum-free cultures to minimize cost in the production bioprocess and in purification of 
target proteins in downstream processes. 
 
Figure 3  Photomicrograph of suspension CHO Cells settled on to tissue culture 
flask bottom. 
 
Modifications in the culture conditions and genetic based engineering of cell lines 
used for production of recombinant targets have played a significant role in optimization 
of production.  A frequent optimization target is arresting the cells in G1 cell cycle phase, 
due to reduced cell growth and higher protein production.  Three methods capable of the 
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growth arrest are: temperature shift, cell engineering, and bioactive chemicals.  
Temperature shifting resulting in cell cycle arrest can improve transcription, translation, 
cytoskeletal rearrangement, with reduced metabolic activity.  The reduced metabolism in 
the cells is reflected in reduction in glucose metabolism and oxygen consumption (Kumar 
et al. 2007; Meleady 2007).  Cell engineering approaches can target the integration of 
genes for over expression such as Bcl-2, a regulatory protein involved in apoptosis 
mediated cell death (Tey et al. 2000).   
 
Figure 4  Schematic of typical batch/fed-batch profile of culture kinetics.  
Production of target protein frequently shows peak accumulation in plateau and the 
decline phase of culture. 
 
2.5 Post Translational Modifications 
It has been found that many protein based biologics require post translational 
processing  for biological activity (Butler 2005).  Glycans on the surface of proteins play 
an important role in immune function.  They are generally specific to a species and non-
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native glycan structures can trigger immune response and high clearance rates of foreign 
proteins from the body.  Improperly glycosylated proteins can trigger immunogenic and 
allergic response and accelerate clearance of the protein from the body.  Glycosylation 
can be affected by the choice of manufacturing process and clonal variation.   
 
Figure 5  Mammalian Cell rProtein processing 
(Note: Similar to NEB diagram (Omasa et al. 2010b)  ) 
 
2.6 Small Molecule Enhancers 
Bioactive molecules can target many cellular mechanisms ranging from metabolic 
to genetic changes.  Important to bioprocessing are molecules that can stimulate the 
improved production of recombinant proteins.  A wide variety of molecules have been 
studied for this purpose, for example quinoline thioethers (Kazi et al. 2010), dimethyl 
sulfoxide (Fiore et al. 2002; Li et al. 2006; Liu and Chen 2007; Liu et al. 2001b; Wang et 
al. 2007), and aurintricarboxylic acid (Liu et al. 2001a).  Additionally, broad classes of 
small molecule in the categories of aromatic carboxylic acids, hydroxamic acids, and 
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Short chain fatty acid (SCFA), a class of saturated monocarboxylic acids, have 
been shown to have many biological functions, including regulating gene transcription 
(Meng et al. 1999) and inhibition of histone deacetylase (Augenlicht et al. 2002).  There 
are a number of SCFA that are important in cells, varying in their carbon backbone 
length; acetate (C2), propionate (C3), butanoate (C4), pentanoate (C5), and caproate 
(C6).  The most widely studied of these, for increased protein production in 
bioprocessing, has been butanoic acid (C4) and has demonstrated a wide effect on cells.  
Butanoic acid has been implicated in cell proliferation, gene transcription regulation, 
differentiation, and apoptosis (Augenlicht et al. 2002; Kim and Lee 2002; Sung et al. 
2004).   Butanoic acid has been shown to stimulate the gene coding for metallothionein.  
Metallothionein (MT) are small cysteine-rich metal binding proteins.  MT plays an 
important role in maintaining zinc and copper homeostasis in cells and can detoxify 
harmful metals such as cadmium (Liu et al. 1992). 
 
Table 2  Select table of SCFA and the antioxidant n-Acetyl Cysteine (Chemical 





CID1# MW Molecular 
Formula 
2D Structure 
Butanoic acid Butanoic 
Acid 
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Pentanoic acid Valeric Acid 7991 102.13 C5H10O2 
 
 
Butanoic acid was demonstrated to increase protein production by Gorman et al 
(Gorman et al. 1983).  An increase in the enhancer-dependent transcription of an SV40 
promoter was approximately 30-fold higher in Hela Cells.  The increased production of 
chloramphenicol acetyltransferase (CAT) in these cells was attributed to the 
hyperacetylation of histones, thus opening the chromatin structure in critical regions 
spanning the enhancer and the adjacent promoter, leading to increased transcriptional 
efficiency.  
The inhibition of histone deacetylase is one of the most widely studied effects of 
butanoic acid treatment.  Inhibition of histone deacetylase leads to hyper-acetylation of 
histone molecules, a class of DNA packaging molecules, which opens gene regions 
making them more readily available for transcription, leading to increased mRNA levels, 
with increasing translation and productivity.  However, butanoic acid has a well-
documented effect of inducing apoptosis in cells it is used to treat.  
Additionally, Butanoic acid has been shown to block cell proliferation in the G1 
cell cycle phase, this may also be a source of increased productivity in some cell lines.  A 
limitation to the use of carboxylic acids is increased levels of apoptosis observed in 
treated cultures. 
The effect of butanoic acid induction of the production of recombinant human 
thrombopoietin (hTPO) produced in Chinese Hamster Ovary cells has been studied for its 
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impact on the heterogeneity and biological activity of the protein (Sung et al. 2004).  The 
human thrombopoietin protein is a highly glycosylated protein with six N-glycosylation 
sites and 24 O-glycosylation sites.  The post-translational glycosylation of recombinant 
proteins has been shown to be effected by the treatment of cultures of CHO cells with 
sodium butyrate (Chung et al. 2001; Santell et al. 1999).  Sung et al. were able to achieve 
a peak hTPO concentration of 82.2 ± 5.6 ug/mL treating cells growing in exponential 
phase with 3 mM butanoic acid.  This group demonstrated that compared to a control 
culture, a 6.4-fold increase in specific productivity, qTPO, and a 3.3-fold increase in 
volumetric productivity on day 7 of the culture.  The butanoic treated culture 
demonstrated diminished protein quality in the form of a lower level of acidic forms of 
hTPO being produced.  Additionally, they demonstrated lower biological activity of the 
butanoic acid treated hTPO.  
Oster et al. demonstrated improved productivity for the recombinant production 
of the plasma extracellular membrane-anchored enzyme, -glutamyl transferase (GGT, 
EC2.3.2.2) by sodium butanoate (Oster et al. 1993).  Using a cytomegalovirus immediate 
early promoter in a CHO cell line, they demonstrate a 3 to 5-fold increase in production 
of GGT.  They observed increase levels of rGGT mRNA production following butanoic 
acid induction.  The resulting rGGT was characterized and demonstrated to be equivalent 
to non-induced control culture rGGT. 
The use of short-chain carboxylic acids such as pentanoic acid (Liu et al. 2001c) 
has been shown to enhance the volumetric productivity of recombinant proteins produced 
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in bioprocesses.  The addition of antioxidants in cultures treated with the carboxylic acid, 
butanoic acid, has lowered the levels of apoptosis observed (Oh et al. 2005).   
Carboxylic acids have demonstrated the ability to improve synthesis of 
recombinant protein in industrially important cell lines such as Chinese Hamster Ovary 
(CHO) cells.  However, some carboxylic acids have been shown to promote an apoptotic 
response in CHO cell culture.  Chi-Hsien Liu, et al(Liu et al. 2001c), researched the small 
molecule enhancement of protein production by a group of nine carboxylic acids by 
themselves and in combination.  They found that the five-carbon carboxylic acid, 
pentanoic acid, showed higher relative protein titer increase compared to the well publish 
butanoic acid counterpart.  They also demonstrated results for lower apoptotic cell effect.  
A number of carboxylic acids, formate, acetate and 2-methyl butyrate showed slight 
enhancement effects on cell growth and production.  Some carboxylic acids, such as L-
alpha-amino-n-butanoic acid showed slight enhancements in growth but no enhancement 
of production.  It was demonstrated that when the carbon backbone range was between 3 
to 5 carbons, there was a marked increase in titer enhancement.  Slightly higher growth 
and a better protein production enhancement were observed for the 5 carbon pentanoic 
acid over the 4 carbon butanoic acid.  To try and explain these results the authors looked 
at apoptosis as an explanation for the results.  Butanoic acid is a well-known enhancer of 
protein production (Lamotte et al. 1999; Mimura et al. 2001), but also has a well-
documented apoptotic affect (Kim et al. 2003).  In these studies, it was found that 
butanoic acid had about double the apoptotic affect that pentanoic acid had using an 
arbitrary apoptosis ratio.  The method used was a cell death detection ELISA kit looking 
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at DNA fragmentation.  Of note in these studies is the relative low producer used in the 
studies.  Whereas a common fusion antibody produces from 500mg to 5 g per liter, the 
cell line used by Liu only produced a maximum of 620 ug per liter, or about 1:800 of a 
common producer cell line.(Preithner et al. 2006) 
It is important that a good process strategy be used to maximize productivity of 
culture(Franco-Lara and Weuster-Botz 2005).   A number of newer small molecule 
enhancers have been developed that are based on aromatic hydrocarbons.  These haven’t 
been compared to pentanoic acid (Allen et al. 2008).   
2.7 Apoptosis 
Apoptosis is programmed cell death triggering a biochemical cascade of events 
leading to cell destruction.  The cascade of the events includes cell blebbing, 
fragmentation of the DNA and the nucleus. 
 
 
Figure 6  Diagram of apoptosis process in cells with illustration of Annexin V and 
Propidium Iodide analysis of cell state. 
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2.8 Antioxidants 
Oxidative stress is a major factor limiting production and quality of product 
produced in recombinant systems.  Many antioxidants have been studied for their 
protective and enhancing effect on cells.  Antioxidants demonstrate the ability to reduce 
stress in the endoplasmic reticulum, a key site of glycosylation (Malhotra et al. 2008). 
2.8.1 Use of Antioxidants in combination with Small Molecule Enhancers 
Antioxidants have been used extensively in cell culture.  An example is the work 
done by Oh et al. (Oh et al. 2005).  This group evaluated a panel of eleven antioxidants 
using a Plackett-Burman statistical design.  In their work they demonstrated that of the 
panel tested only n-Acetyl cysteine (NAC), seen in Table 3, showed increased longevity 
of cell culture and increased production of the target protein, recombinant interferon-β-
1A (IFN-β).  In butanoic acid treated cells, NAC treatment was able to extend culture 
longevity greater than 8 days and increased recombinant INF-β production 2-fold when 
compared to control cultures that were treated only with butanoic acid.  They further 
demonstrated that the glycosylation patterns of the INF-β, studied using isoelectric 
focusing (IEF), showed increased levels of lower pI isoforms compared to the control 
run.  The recombinant INF-β from NAC treated cultures had a 17.7% higher level of 
sialic acid content when analyzed by HPLC. 
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Table 3  Chemical Description of n-Acetyl cysteine. 
Common 
Name 









12035 163.19 C5H9NO3S 
 
 
2.9 Chinese Hamster Ovary Cell Line 
Production of biopharmaceuticals has come to rely on mammalian cells; in 
particularly they have come to rely on Chinese Hamster Ovary cells.  The predominant 
cell line used in the production of biopharmaceuticals is the Chinese Hamster Ovary 
(CHO) cell line (Jayapal et al. 2007).  This cell line was derived from a female Cricetulus 
griseus hamster in 1957, by Dr Theodore Puck in the Department of Medicine at the 
University of Colorado.  Cricetulus griseus have a low chromosome number (2n=22).  
The key cell line used in biopharmaceutical production, derived from C. griseus, CHO-
K1, has been shown to be heteroploidy.  It was observed early on that the cell line was 
relatively easy to cultivate in vitro and had a good growth rate, with specific growth rates 
that can range from 0.04 - 0.06 hr-1. 
Important to the development of CHO cells for biopharmaceutical production 
were observations of the CHO genome being relatively easily manipulated and the 
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(DHFR)  selection and amplification system and the glutamine synthetase (GS) selection 
and amplification system (Camire 2000).  The DHFR expression system relies on the 




Figure 7  Schematic of DHFR enzyme process. 
 
Important to the development of this expression system was the development of 
DHFR knockout cell lines in Dr. Larry Chasin’s lab at Columbia University.  The CHO 
DUKX B11 and the CHO DG44 cell lines are single and double allele knockouts of the 
DHFR gene, respectively, and were generated by the use of mutagens.  In the absence of 
nucleic acids and the precursors hypoxanthine and thymidine, these cell lines cannot 
replicate and unsupplemented populations die off.  Incorporating the DHFR gene into an 
expression cassette with a gene of interest allows the recombinant cell line to live in a 
selection medium without nucleic acid precursors and hypoxanthine and thymidine.  
Another important feature of this system is the dose response competitive inhibition of 
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the DHFR enzyme by the compound methotrexate (CAS Number 133073-73-1).  By 
increasing the concentration of methotrexate in a culture of CHO cells with an expression 
cassette containing DHFR, successive populations of cells that have increasing copies of 
DHFR and the corresponding gene of interest are selected for.  In this way gene copy 
number amplified populations can be selected that can have two to thousands of desired 
genes (Kaufman et al. 1985). 
The GS expression system relies on the conversion of glutamate and ammonium 
to the amino acid glutamine (Figure 8).  This system has been shown to be effective in 
both knockout and wild-type cell lines containing a native GS gene. Similar to DHFR 
expression systems the glutamine synthesis enzyme can be competitively inhibited by 





 8  Schematic of GS selection system. 
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Chapter 
 SCREENING OF SHORT CHAIN FATTY ACIDS AND AN ANTIOXIDANT WITH 
CHINESE HAMSTER OVARY CELLS 
 
3.1 Introduction 
Tissue plasminogen activator (tPA) is a 68 kDa monomeric serine protease (EC 
3.4.21.68) produced primarily by endothelial cells.  In blood, it is one of two major activators of 
plasminogen, the precursor of plasmin which is a serine protease that can dissolve fibrin blood 
clots.  A recombinant form of the protein is produced as a biopharmaceutical drug, Activase®, 
for treatment of acute myocardial infarction, acute ischemic stroke, pulmonary thrombosis, and 
other blood clot conditions (Wagstaff et al. 1995).  Its production is done in CHO cells and acts 
as a model for non-IgG biopharmaceutical recombinant protein production systems. 
Bioactive chemicals can target many cellular mechanisms including protein expression.  
One of the targeted mechanisms is to induce cell stress to cause up regulation of protein 
production.  A wide variety of molecules have been used to promote increased protein 
production in recombinant cell lines, for example quinoline thioethers (Kazi et al. 2010), 
dimethyl sulfoxide (Fiore et al. 2002; Li et al. 2006; Liu and Chen 2007; Liu et al. 2001b; Wang 
et al. 2007), and aurintricarboxylic acid (Liu et al. 2001a).  Additionally, broad classes of small 
molecule in the categories of aromatic carboxylic acids, hydroxamic acids, and acetamides have 
been studies (Allen et al. 2008). 
One of the most studied molecules for stimulation of protein production is butanoic acid.  
Butanoic acid is a short chain fatty acid (SCFA), a class of saturated monocarboxylic acids.  
SCFA have been shown to have many biological functions, including regulating gene 
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transcription (Meng et al. 1999) and inhibition of histone deacetylase (Augenlicht et al. 2002).  
There are a number of SCFA that are important in cells; acetate (C2), propionate (C3), butanoate 
(C4), pentanoate (C5), and caproate (C6).  The most widely studied of these has been butanoic 
acid (C4) and has demonstrated a wide effect on cells (Table 3).  Butanoic acid has been 
implicated in cell proliferation, gene transcription regulation, differentiation, and apoptosis 
(Augenlicht et al. 2002; Kim and Lee 2002; Sung et al. 2004).   Butanoic acid has been shown to 
stimulate the gene coding for metallothionein.  Metallothionein (MT) are small cysteine-rich 
metal binding proteins.  MT plays an important role in maintaining zinc and copper homeostasis 
in cells and can detoxify harmful metals such as cadmium (Liu et al. 1992). 
Butanoic acid was demonstrated to increase protein production of by Gorman et al 
(Gorman et al. 1983).  An increase in the enhancer-dependent transcription of an SV40 promoter 
was approximately 30-fold higher in Hela Cells.  The expression increases of chloramphenicol 
acetyltransferase (CAT) in these cells was attributed to the hyperacetylation of histones, thus 
opening the chromatin structure in critical regions spanning the enhancer and the adjacent 
promoter, leading to increased transcriptional efficiency.  
The inhibition of histone deacetylase is one of the most widely studied effects of butanoic 
acid treatment.  Inhibition of histone deacetylase leads to hyper-acetylation of histone molecules, 
a class of DNA packaging molecules, which opens gene regions making them more readily 
available for transcription, leading to increased mRNA levels increasing translation and 
productivity.  However, butanoic acid has a well-documented effect of inducing apoptosis in 
cells it is used to treat. 
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3.2 Materials and Methods 
3.2.1 Cell Line and Media 
A Chinese Hamster Ovary cell line, CHO 1-15500 (ATCC® CRL-9606), producing 
human tissue Plasminogen Activator (tPA) was used for these studies.  The cell line had 
previously undergone dihydrofolate selection and amplification with 50 nM methotrexate. The 
cell line was cultured using the chemically-defined serum-free medium CDM4CHO® (HyClone, 
Thermo Fisher Scientific, Waltham, Massachusetts) with 4mM L-Glutamine.  Cell stocks were 
maintained in 100 mL cultures in 250 mL shake flask in a 37°C, 5%CO2 incubator, passaged 
every 3 to 4 days.   
3.2.2 Component Preparation 
All compound tested were prepared in deionized process water and were sterile filtered 
using 0.2 um sterilizing grade bottle top filters.  Butanoic Acid, n-Acetyl –cysteine, 
hydrocinnamic acid, 4-Phenylbutanoic acid were prepared at a concentration of 250mM and 
Pentanoic acid was prepared at a concentration of 500mM. 
3.2.3 Bioprocess Experiments 
Disposable 125mL Erlenmeyer shake flasks were used for scale-down culture analysis of 
the short chain fatty acids and n-acetyl cysteine.  Experimental conditions were cultured using a 
base formulation of CDM4CHO® (HyClone, Thermo Fisher Scientific, Waltham, 
Massachusetts) in a fed batch process using a custom formulation process supplement PS320 
(HyClone, Thermo Fisher Scientific, Waltham, Massachusetts).  The PS320 process supplement 
contains carbohydrates, amino acids, and vitamins.  This formulation, PS320:608.0, was prepared 
at a concentration of 60g/L by using adjustments to pH 9.0 with 1N NaOH followed by 
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adjustment with 1.0 HCl to pH 8.0 followed by the addition of 3.2 g/L sodium bicarbonate.  The 
formulation was then sterile filtered using a 0.2 um sterilizing grade bottle top filter.  
A single 2.8 L disposable Fernbach flask was seeded at an initial volume of 600 mL 
(0.8Vf) at a cell density of 250,000 cells/mL on day 0.  The culture was fed two times with 75 
mL (0.1Vf)  PS320:608.0 on day 3 and on day 5.  Following the feeding of the culture on day 5, 
cells were distributed into independent culture flasks in preparation for treatment with designated 
culture test conditions.  Cultures were sampled on days 0, 3, 5, 7, and 10 for cell quantitation, 
viability analysis and product titer.   
3.2.4 Cell Quantitation 
Cell density and viability were determined using Trypan Blue dye exclusion assays.  
Microtiter plate cultures were counted using on a Cellavista® Cell Imager (SynenTec, Elmshorn, 
Germany).  Shaker flask cultures were counted using an automated ViCell® XR Cell Viability 
Analyzer (Beckman Coulter, Fullerton, California).  Aliquots for cell counting were counted 
immediately after sampling.   
3.2.5 Product Titer Analysis by Enzyme-Linked Immunosorbent Assay 
Product titer was determined using a sandwich enzyme-linked immunosorbent assay 
(ELISA).  An affinity purified sheep anti-tPA IgG was used as a capture antibody by coating a 
standard ELISA 96 well plate.  A reference standard curve was generated using a concentrated 
and titered recombinant tPA control in the range of 3.16 to 1000 ug/mL.  Samples from culture 
conditions which had previously been stored frozen at -20°C were thawed and dilutions were 
prepared in phosphate buffered saline (PBS) at a dilution factor of 1:2000.  Samples were then 
applied to the capture antibody prepared ELISA plates.  A sheep anti-tPA conjugated to horse-
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radish peroxidase was used as the detecting antibody.  A stable liquid one-step 3,3′,5,5′-
tetramethylbenzidine (TMB) liquid was used as a substrate for colorimetric analysis.  A 
SpectraMax M2 (Molecular Devices, Sunnyvale, CA) was used to analyze the assay plates at a 
detection wavelength of 450 nm. 
𝐼𝑉𝐶𝐷 = 𝑥 𝑑𝑡 
𝐼𝑉𝐶𝐷 =
𝒚𝒊 + 𝒚𝒊 𝟏
𝟐
∗ (𝒙𝒊 − 𝒙𝒊 𝟏)
𝒊
 
3.3 Results and Discussion 
To determine the effect of multiple small molecules and an antioxidant for their potential 
to enhance volumetric protein production, a CHO cell line producing tPA was subjected to 
gradients of the components (Figure 9). 
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The fed batch control condition showed a large decline following day 7.  A significant 
improvement was observed in the cell growth for samples treated with n-Acetyl-Cysteine.  The 
n-Acetyl-Cysteine cell conditions didn’t suffer the precipitous decline in cell density and 
viability observed with the fed-batch control.  This may be attributed to a large decline in 
viability at this point (Figure 10). 
 
Figure 
 9  Growth promotion analysis of carboxylic acid treatment conditions. 
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Higher concentration treatments at the 5 mM level of Sodium Butyrate, Pentanoic acid, 
Hydrocinnamic acid, and 4-Phenylbutyric acid showed almost complete inhibition of cell growth 




 10 Plot of viability for carboxylic acid treatment conditions. 
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The largest volumetric productivity increase was observed in the 5mM Sodium Butyrate 
treatment condition, 72.01 mg/L (Table 1).  However, Pentanoic acid showed a loss of 
volumetric productivity at 2.5 mM and 5.0 mM treatment levels.  The peak volumetric 
productivity at 1.25 mM Pentanoic acid was 50.93 mg/L which was only 70.7% of the peak 




 11  Growth promotion of 5mM concentrations components causing reduced performance. 
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Table  5  Result of gradient testing of select SME and the antioxidant NAC. 
   
ICA (cell-
days/mL) 








Fed batch Control Control 0.000 34.05 48.03 1.41 
NAC 2.5 mM NAC 2.500 45.25 62.19 1.37 
NaBu 5 mM NB 5.000 22.04 72.01 3.27 
PA 1.25 mM PA 1.250 34.56 50.93 1.47 
HCA 0.625 mM HCA 0.625 36.70 43.14 1.18 
4PBA 0.625 mM 4PBA 0.625 26.80 24.74 0.92 
 
 
Considering the integral cell area of treatment conditions, n-Acetyl-Cysteine showed 
decline in culture performance at the 10mM level compared to the 5mM level, 31.21 cell-
days/mL compared to 45.83 cell-days/mL, respectively, a 31.9% drop.  Peak volumetric 
productivity for n-Acetyl-cysteine, 62.19 mg/L was observed at 2.5 mM which was 64.2% 
higher than that observed at the peak cell performance level at the 5mM concentration. 
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Figure 12 Plots of Integral Cel lArea , Viability, and Specific Productivity for n-Acetyl 
Cysteine (NAC), Sodium Butyrate (NB), and Pentanoic Acid (PA) condictions. 
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Figure 13 Plots of Integral CellArea , Viability, and Specific Productivity for Sodium 
Butyrate (NB), Hydrocinnamic Acid (HCA), and 4-Phenylbutanoic Acid (4PBA). 
 
3.4 Conclusion 
Multiple small molecules were demonstrated to show gradient dependent response to cell 
growth and protein production.  In this tPA producing cell line the best protein production was 
seen in cultures induced with butanoic acid.  The short-chain fatty acid pentanoic acid was able 
to improve productivity compared to the fed-batch control, but to a lower level than butanoic 
acid.  The antioxidant, n-acetyl cysteine, was the only molecule evaluated in the test to show a 
marked improvement in cell densities over the testing gradient. 
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Chapter 
 IMPROVED GROWTH AND RECOMBINANT PROTEIN PRODUCTIVITY IN CHO 
CELLS USING THE COMBINED EFFECTS OF SHORT CHAINFATTY ACIDS WITH 
THE ANTIOXIDANT N-ACETYLE CYSTEINE 
 
4.1 Introduction 
Within biopharmaceuticals, monoclonal antibodies are an important segment.  Seven of 
the top ten selling biopharmaceuticals in 2011 were monoclonal antibodies or fragments of 
monoclonal antibodies.  Monoclonal antibodies are natural occurring glycosylated proteins that 
play a major role the body’s immune system.  They are monospecific to an epitope target and are 
produced by B lymphocytes, a class of immune cells, in response to an antigen.  Specific B 
lymphocytes only produce one specific antibody.  One method for producing the B cell needed 
for the fusion is to expose a mouse to an antigen in two phases, a priming dose and a booster 
dose.  Following treatment with the antigen a sample of the spleen can be harvested.  In 1975, 
George Kohler and Cesar Milstein demonstrated that a specific B cells could be isolated and 
fused with a cancerous myeloma cell line.  The B cell bringing the ability to produce a specific 
antibody and the myeloma cell conferring the ability to replicate rapidly and indefinitely.  This 
process, known as hybridoma technology, ushered in a process to allow expanded production of 
a monoclonal antibody to a specific target molecule.  Following fusion with the myeloma cell 
line the hybridoma population can be screened for a population producing the antibody of 
interest. 
Most therapeutics monoclonal antibodies are either humanized or are human 
immunoglobulins (IgG) and are produced as recombinant glycoproteins in mammalian cells 
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(Beck et al. 2008).  Despite their rapid growth in use, they are generally expensive therapies that 
can cost over $100,000 per year or over the course of full treatment (Bioplan Associates 2013).  
The high cost of MAb treatment can be attributed to low potency and short half-life, requiring 
large dosages and frequent dosages.  These factors lead to large amounts of MAb being needed 
to treat patient populations.  It is estimated that around 90% of the world-wide production 
capacity for mammalian cell culture is for MAb production (Bioplan Associates 2013).  Much of 
this production requires the use of large volume bioreactors at the 10,000 L scale.  During 
process development and scale-up one of the primary engineering objectives is to optimized the 
production process to minimize manufacturing costs. 
In an effort to target optimization of recombinant protein production of IgG in CHO cell 
lines we sought to analyze the growth and recombinant protein production response to the novel 
combination of pentanoic acid induction of protein production and the combined treatment with 
the anti-oxidant n-Acetyl Cysteine to minimize detrimental response by the cultured cells to 
treatment with the carboxylic acids. 
4.2 Materials and Methods 
A Chinese Hamster Ovary cell line producing a monoclonal antibody (IgG) was used for 
these studies. Seed stocks of the previously suspension adapted cell line were brought out of 
cryopreservation and were cultured with CDM4CHO® (HyClone, Thermo Fisher Scientific, 
Waltham, Massachusetts).  This cell stock was cultured in volume of 100 mL in 250 mL 
disposable Erlenmeyer shake flasks in a 37°C, 5%CO2 incubator, passaged every 3 to 4 days.  
Cultures were agitated on a shaker platform at 135 RPM with loosened caps to maintain 
adequate gas exchange. 
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4.2.1 Cell Line and Media 
A Chinese Hamster Ovary cell line producing a monoclonal antibody (IgG) was used for 
these studies. The cell line was cultured with CDM4CHO® (HyClone, Thermo Fisher Scientific, 
Waltham, Massachusetts).  Cell stocks were maintained in 200 mL shake flask cultures in a 
37°C, 5%CO2 incubator, passaged every 3 to 4 days. 
4.2.2 Component Preparation 
Butanoic Acid and pentanoic acid were prepared at a concentration of 250mM in 
deionized water.  N-Acetyl –cysteine was prepared at a concentration of 500mM in deionized 
water.   
4.2.3 Bioprocess Experiments 
A time course, repeated measure study of the two short chain fatty acids, pentanoic acid 
and butanoic acid, were studied independently with n-acetyl cysteine in 5 x 5 factorial designs.  
Pentanoic acid and butanoic acid were run from 0 – 5 mM in a two-fold serial dilution gradients 
and n-acetyl cysteine was run from 0 – 10 mM in two-fold serial dilution gradients.  The samples 
were randomized and run in triplicate.  Conditions were 1.0 mL cultures run in deep-well 96 well 
microtiter plates (Nunc, Thermo Fisher Scientific, Waltham, Massachusetts). 
Experimental conditions were cultured in a basal formulation of CDM4CHO® 
supplemented with 6 g/L Cell Boost 2® (HyClone, Thermo Fisher Scientific, Waltham, 
Massachusetts) process supplement.  Cultures were maintained in a 37C, 5%CO2 incubator 
active humidification at a relative humidity of 80%.  Mixing was provided by orbital shaking at 
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1,000 RPM with a 3mm orbit.  Culture sterility was maintained using rayon fabric covers to seal 
the plates. 
All culture conditions were inoculated at 250,000 cells/mL on day 0 and were induced 
with butanoic acid or pentanoic acid on day 4.  Supplementation of culture with NAC was done 
at the time of small molecule induction.  Cultures were sampled on days 0, 3, 5, 7, and 10 for cell 
quantitation and product titer.   
4.2.4 Cell Quantitation 
Cell density and viability were determined using.  Trypan blue, a dead-cell dye, excluded 
by viable cells was used to distinguish the two different cell populations.  A high throughput 
image cytometer, Cellavista ® Cell Imager (SynenTec, Elmshorn, Germany), was used to count 
microtiter plate samples of culture conditions.  Aliquots for cell counting were counted 
immediately after sampling.   
4.2.5 Product Titer Analysis by Biolayer Interpherometry 
Samples of 40uL from culture conditions were diluted in phosphate buffered saline (PBS) 
in standard 96 well SBS microtiter plates and were kept frozen at -20°C until analysis.  Product 
titer was determined using a biolayer interpherometry assay with Protein A biosensors using an 
Octet QK384 (Fortebio, Menlo Park, CA).  A reference standard was generated using a human 
IgG (Sigma Aldrich, St. Louis, MO) in the range of 3.16 to 1000 ug/mL.  
4.3 Results and Discussion 
4.3.1  Effects of Butanoic and Pentanoic Acids in combination with N-Acetyl Cysteine on 
Cell Growth Profiles Density 
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The treatment of a CHO cell line producing a recombinant IgG with small molecule 
enhancers and the anti-oxidant n-acetyl cysteine was analyzed in a scale-down model using 
deep-well microtiter plates.  The cultures demonstrated expected growth response (Figure14) to 
treatments.  Significant loss in viable cells was observed in cultures treated with higher 
concentrations of small molecule enhancers. Loss of viable cells was observed in cultures treated 
with higher concentrations of small molecule enhancers. Higher peak growth was observed in 
cultures treated with pentanoic acid relative to cultures treated with butanoic acid (Figure 16). 
 
Butanoic acid induction in combination with NAC, in a high throughput response surface 
methodology design, at a concentration of 0.625 mM butanoic acid and 1.25 mM n-acetyl 
cysteine, had a 6.2% increase in growth (Figure14A) compared to the untreated control.  At the 
same concentration of butanoic acid, but no NAC supplementation the growth was decreased by 
 
Figure 14  Response Surface growth promotion study. (A) Butanoic acid and n-acetyl 
cysteine.  (B)  Pentanoic acid and n-Acetyl Cysteine. 
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34.6% compared to the non-treated control compared to the 1.25mM NAC treated cultures at the 
same butanoic acid concentration. 
Pentanoic acid induction in combination with NAC, at a concentration of 0.625 mM 
pentanoic acid and 1.25 mM n-acetyl cysteine, had a 16.6% increase in growth (Figure14B) 
compared to the untreated control.  At the same concentration of pentanoic acid, but no NAC 
supplementation the growth was increased by 16.6% compared to the non-treated control and 
compared to the 1.25mM NAC treated cultures at the same pentanoic acid concentration. 
Higher peak growth was observed in cultures treated with pentanoic acid relative to 
cultures treated with butanoic acid.  Interestingly, there was improvement in growth of CHO 
cultures treated with pentanoic acid relative to the untreated control sample, but this wasn’t 
observed in butanoic acid treated samples (Figure 15). 
 
 
Figure 15  Plot of growth performance of CHO cells with combined Pentanoic Acid (PA) 
and n-Acetyl Cysteine treatment (NAC) compared to untreated control. 
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4.3.2 Effects of Butanoic and Pentanoic Acids in combination with N-Acetyl Cysteine on 
Volumetric Productivity 
Comparison of the treatment of cultures with various levels of pentanoic acid and 
butanoic acid with the addition of anti-oxidant didn’t show major differences in volumetric 
productivity (Figure 16), but did show variation in concentration for peak productivity.  Peak 
productivity was observed for butanoic acid and NAC at 0.625 mM and 1.25 mM, respectively.  




Butanoic acid induction in combination with NAC, in a high throughput response surface 
methodology design, at a concentration of 0.625 mM butanoic acid and 1.25 mM n-acetyl 
Figure 
 16  Response Surface of production of IgG.  (A) Butanoic acid and n-acetyl cysteine.  (B)  
Pentanoic acid and n-Acetyl Cysteine. 
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cysteine, a 3.52 factor increase in production of IgG (Figure 17) compared to the untreated 
control.  At the same concentration of butanoic acid, but no NAC supplementation produced 
87.3% less IgG compared to the 1.25mM NAC treated cultures at the same butanoic acid 
concentration. 
Pentanoic acid induction in combination with NAC, in a high throughput response 
surface methodology design, at a concentration of 1.25 mM pentanoic acid and 1.25 mM n-
acetyl cysteine, a 3.68 factor increase in production of IgG (Figure 18) compared to the untreated 
control.  At the same concentration of pentanoic acid, but no NAC supplementation produced 




Figure17  Butanoic Acid and n-Acetyl Cysteine treatment. 


























Figure18  Pentanoic Acid and n-Acetyl Cysteine treatment. 
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Conclusion 
Using the antioxidant n-acetyl cysteine we have shown improved production of IgG in a 
CHO cell line cultured with pentanoic acid used as an enhancer of protein production.  The 
improvement in productivity with the combined treatment of pentanoic acid and n-acetyl 
cysteine correlated with improved viability.  Co-supplementation of the two molecules may be 
an effective tool for use in optimization of cell culture bioprocesses.  Butanoic acid and 
pentanoic acid can induce increased production of recombinant IgG in CHO cells.  
Supplementation of n-acetyl cysteine to pentanoic acid induced cultures can further increase IgG 
production increases.  
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Chapter 
 DECREASED APOPTOTIC EFFECT USING THE ANTIOXIDANT N-ACETYLE 
CYSTEINE IN COMBINATION WITH TREATMENT OF CHO CELLS WITH THE 
SHORT CHAIN FATTY ACIDS BUTANOIC ACID AND PENTANOIC ACID 
 
5.1 Introduction 
Tissue plasminogen activator (tPA) is a 68 kDa monomeric serine protease (EC 
3.4.21.68) produced primarily by endothelial cells.  In blood, it is one of two major activators of 
plasminogen, the precursor of plasmin which is a serine protease that can dissolve fibrin blood 
clots.  A recombinant form of the protein is produced as a biopharmaceutical drug, Activase®, 
for treatment of acute myocardial infarction, acute ischemic stroke, pulmonary thrombosis, and 
other blood clot conditions (Wagstaff et al. 1995).  It is a recombinantly produced protein and is 
made in CHO cells and acts as a model for non-IgG biopharmaceutical recombinant protein 
production systems. 
5.2 Materials and Methods 
5.2.1 Cell Line and Media 
A Chinese Hamster Ovary cell line, CHO 1-15500 (ATCC® CRL-9606), producing 
human tissue Plasminogen Activator (tPA) was used for these studies. The cell line was cultured 
with CDM4CHO® (HyClone, Thermo Fisher Scientific, Waltham, Massachusetts).  Cell stocks 
were maintained in 200 mL shake flask cultures in a 37°C, 5%CO2 incubator, passaged every 3 
to 4 days. 
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Experimental conditions were cultured in CDM4CHO® supplemented with 2 g/L Cell 
Boost 2® (HyClone, Thermo Fisher Scientific, Waltham, Massachusetts) process supplement. 
5.2.2 Component Preparation 
Butanoic Acid was prepared at a concentration of 250mM in deionized water.  Pentanoic 
acid was prepared at a concentration of 250mM in deionized water.  N-Acetyl Cysteine was 
prepared at a concentration of 500mM.   
5.2.3 Bioprocess Experiments 
Disposable shake flasks were used for 50 mL scale-down culture testing of butanoic acid 
and pentanoic acid with n-Acetyl Cysteine supplementation for studying apoptosis and 
productivity. 
Disposable 125 mL Erlenmeyer shake flasks were used for 50 mL scale-down culture 
testing of butanoic acid and pentanoic acid with n-acetyl cysteine supplementation for studying 
apoptosis and productivity.  Cultures were maintained in a non-humidified 37C, 5%CO2 
incubator.  Mixing was provided by an orbital shaker, shaken at 135 RPM with a 19 mm orbit.   
All culture conditions were inoculated at 250,000 cells/mL on day 0 and were induced 
with butanoic acid or pentanoic acid on day 3.  Supplementation of culture with NAC was done 
at the time of small molecule induction of cultures.  Cultures were sampled on days 0, 3, 4, 5, 6, 
7, and 10 for cell quantitation and product titer.  Apoptosis was analyzed on day 6, three days 
post induction with butanoic acid and pentanoic acid.  
5.2.4 Cell Quantitation 
Cell density and viability were determined using Trypan Blue dye exclusion assays.  
Microtiter plate cultures were counted using on a Cellavista® Cell Imager (SynenTec, Elmshorn, 
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Germany).  Shaker flask cultures were counted using an automated ViCell® XR Cell Viability 
Analyzer (Beckman Coulter, Fullerton, California).  Aliquots for cell counting were counted 
immediately after sampling.   
5.2.5 Apoptosis Analysis by Flow Cytometry 
Apoptosis, genetically programmed cell death, is a natural response for removal of 
unwanted cells (Elmore 2007).  The process of programmed cell death is characterized by 
multiple cellular events; chromatin condensation, cell volume loss, DNA fragmentation, and the 
loss of phospholipid membrane integrity.  The loss of phospholipid membrane integrity results in 
phosphatidylserine (Bratton et al. 1997) exposure on the extracellular cell membrane.  
Phosphatidylserine, a negatively charged phospholipid component of the inner cell membrane, 
when exposed on the outer cell membrane signals recognition of the of the apoptotic cells 
initiating a non-inflammatory phagocytic response. 
Annexins are a family of proteins that bind to cell membranes.  Annexin V binds with 
high specificity to phosphatidylserine.  The binding takes place rapidly with high affinity and is 
dependent on calcium for binding. 
Apoptosis was analyzed following treatment of cells with butanoic acid or pentanoic acid 
combined with treatment by n-Acetyl Cysteine.  Early apoptosis was monitored by 
phosphatidylserine exposure on the cell surface using an fluorescein isothiocyanate labeled 
Annexin V (Vermes et al. 1995).  To distinguish dead cells from apoptotic cells propidium 
iodide was used to label dead cells.  Propidium iodide is a fluorescent molecule that intercalates 
in dead cell and binds with nucleic acids.  Annexin V, propidium iodide treated cells were 
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analyzed using a BD Accuri™ C6 Flow Cytometer (BD Biosciences, San Jose, CA) with a 
HyperCyt® Autosampler (Intellicyt Corporation, Albuquerque, NM). 
5.2.6 Product Titer Analysis by Enzyme-Linked Immunosorbent Assay 
Product titer was determined using a sandwich enzyme-linked immunosorbent assay 
(ELISA).  An affinity purified sheep anti-tPA IgG was used as a capture antibody by coating a 
standard ELISA 96 well plate.  A reference standard curve was generated using a concentrated 
and titered recombinant tPA control in the range of 3.16 to 1000 ug/mL.  Samples from culture 
conditions which had previously been stored frozen at -20°C were thawed and dilutions were 
prepared in phosphate buffered saline (PBS) at a dilution factor of 1:2000.  Sample were then 
applied to the capture antibody prepared plates.  A sheep anti-tPA conjugated to horse-radish 
peroxidase was used as the detecting antibody.  A stable liquid one-step 3,3′,5,5′-
tetramethylbenzidine (TMB) liquid was used as a substrate for colorimetric analysis.  A 
SpectraMax M2 (Molecular Devices, Sunnyvale, CA) was used to analyze the assay plates at a 
detection wavelength of 450 nm.   
5.3 Results and Discussion 
The addition of the anti-oxidant n-Acetyl Cysteine to the culture of CHO cells producing 
a recombinant protein ameliorated the apoptotic effect of carboxylic acid treatment with butanoic 
acid and pentanoic acid. 
5.3.1 Effects of Butanoic Acid and Pentanoic Acid in combination with N-Acetyl Cysteine on 
Apoptosis 
The treatment of CHO IgG cell line producing a recombinant IgG1 was cultured in small 
volume shake flasks.    Cultures were treated with different levels of butanoic acid, pentanoic 
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acid, and the anti-oxidant n-acetyl cysteine (NAC) on day 3.  On day 7 samples were analyzed 
for apoptosis using Annexin V and propidium iodide with analysis by flow cytometry.  Annexin 
V was used identify cells that were entering early apoptosis and propidium iodide was used to 
identify cells that had died.  The control culture had a viability of 86.9% (Table 6) and showed 
normal growth characteristics. 
 
 
Figure 19  Flow cytometry analysis of carboxylic acid treatment with the antioxidant n-
Acetyl Cysteine compared to an untreated control. 
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Table 6  Viability of combined carboxylic acid and antioxidant treatment. 
 
Table 7  Early Apoptosis results of combined carboxylic acid and antioxidant treatment. 
 
 
The culture treated with n-acetyl cysteine only showed minimal improvements in culture 
viability and cells not entering early apoptosis (Table 6), 1.4% and 1.3%, respectively.  
Treatment of cultures with sodium butyrate and NAC showed minimal improvement in viability 
but improved the percentage of cells entering early apoptosis by 5.3% (Table 6).   Pentanoic acid 
and NAC treated culture demonstrated 6.4% improvement in viability and 10.0% improvement 
in preventing cells from entering early apoptosis (Table 7).  All conditions showed improved 
productivity relative to the untreated control (Table 8).  In this study butanoic demonstrated a 
5.7% loss in productivity when treated with NAC, however, pentanoic acid treatment with NAC 
demonstrated an improvement in productivity of 19.5% (Figure 8). 
5.3.2 Comparison of Viability, Early-Apoptosis and Productivity Improvement  
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Treatment of pentanoic acid containing culture with n-acetyl cysteine demonstrated a 
19.5% increase in productivity and a 7.3% increase in viability (Table 8).  A reduction of 5.72% 
in the amount of IgG produced was observed in butanoic acid cultures treated with the 
antioxidant n-acetyl cysteine.  Reduced levels of apoptosis were observed in cultures of both 
pentanoic acid and butanoic acid. 




Butanoic acid is a well-known small molecule enhancer of protein production, but 
induces apoptosis in many different cell types.  n-Acetyl Cysteine is a thiol containing anti-
oxidant that has been shown to reduce apoptosis induction by butanoic acid.  Pentanoic acid has 
been shown to have similar properties for inducing higher production levels of proteins.  We 
have been able to demonstrate that pentanoic acid can improve protein production.   It also 
shows increased apoptosis, which can be delayed by treatment with n-acetyl cysteine.   
Here it was shown that pentanoic acid can improve the volumetric production of IgG in 
CHO cells treated during log phase growth.  This stimulation was positive but didn’t achieve the 
productivity levels achieve with butanoic acid supplementation.  Pentanoic acid experiments 
showed similar improvements in productivity to those observe by Liu et al.  (Liu et al. 2001c).   
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We were able to show apoptosis markers in conditions treated with both pentanoic acid 
and butanoic acid.  Although the supplementation of the anti-oxidant n-Acetyl Cysteine into both 
treatments showed improvements in cell health, only pentanoic acid showed improvement 
productivity.  We did observe further performance increases to those previously observed by 
others for increased productivity with the addition of anti-oxidants (Oh et al. 2005).  However, 
the overall volumetric productivity was 1.7-fold higher in butanoic acid treated cultures.   
5.5 Conclusion 
As seen in previous studies, pentanoic acid wasn’t able to stimulate higher productivity 
than butanoic acid.   However, the combined treatment with the antioxidant n-acetyl cysteine was 
able to improve productivity in pentanoic acid treated cultures to a greater degree, than butanoic 
acid treated conditions.  Apoptosis reduction by treatment with n-acetyl cysteine in cultures 
induced with carboxylic acid was shown to be a viable method to improve productivity.  
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Chapter 
 SUMMARY, CONCLUSIONS, AND RECOMMONDENDATIONS 
6.1 Summary and Conclusions 
In an effort to optimize the bioprocess manufacturing of recombinant proteins by 
increasing the volumetric titer, the combination for protein induction of the short chain fatty acid 
pentanoic acid and the antioxidant n-acetyl cysteine is a viable method for process evaluation.  
The improvement in productivity with the combined treatment correlated with improved viability 
and a reduction in cells entering apoptosis.  Butanoic acid and pentanoic acid were both shown to 
induce increased production of recombinant IgG in CHO cells.  The levels of improved protein 
production were shown to be cell line dependent for both of these carboxylic acids. 
6.2 Recommendations 
A. Perform scale-up testing of scale-down testing from research.  In these studies, scale-
down models of larger bioprocess systems were used.  Benchtop bioreactors allow the 
testing of the samples under more controlled conditions, specifically of control dissolved 
oxygen (DO) and pH conditions.  These factors being held at a steady state level allow 
optimization to add in specific parameter controls at targeted levels.  
B. Study in chemostat culture would allow for steady analysis looking at changes in oxygen 
consumption, glucose consumption, lactic acid production, protein production, death rate 
and growth rate under various steady-state conditions. 
C. Investigate effect of genetic modification of the cell line, by such things as bcl-2 
overexpression with addition of various small molecule enhancers of production. 
D. Test mechanism of action of PA and other SME for HDAC activity. 
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E. New clones are invariably different, so design and development of standardized screening 
process can allow rapid identification of optimization pathways. Other cell lines such as 
CHO1-15, non-IgG producers 
F. SME.   Perform broad screening assays of small molecule enhancers of protein 
productivity.  This can be achieved by development of high throughput screening assays 
under appropriate culture conditions.  Molecule that could be screened are short-chain 
fatty acids (SCFA), including butanoic acid and pentanoic acid, aromatic carboxylic 
acids, hydroxamic acids, acetamides, DMSO, rapamycin, etc.  Screening can narrow 
down the scope of analysis allowing best performers to proceed to additional testing.    
G. Antioxidants.  Develop a high throughput screening assay of a broad spectrum of 
antioxidants.  Look at antioxidants such as what are the classes of antioxidants. 
H. Combined effect of antioxidants and SME’s.  Look at different screening designs to 
determine if their combinations of SME may act synergistically to improve productivity. 
I. Analyze small molecule enhancers effect on cell cycle.  Is there a particular supplement 
that will improve the cell survival of samples in the G0 cell cycle? 
J. Look at critical quality attributes.  Study the glycosylation pattern of SME treated and 
AOx treated.  Glycosylation deamidation.  Protein aggregates.  Bioactivity. Look at Sialic 
acid content of antibodies.  Maybe Lectin binding. Look at protein aggregation, sequence 
truncation, and charge variants. Determine if there is a time-coarse variation in change of 
critical quality attributes.  (Sung and Lee 2005) Final product activity assay. 
K. Focus comparison of feeding strategies effect on induction. Low temperature shift 
combined affect. Analyze effect of SME addition rate of apoptosis.  Rather than a bolus 
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induction, could a slow addition improve effect while minimizing negative effects like 
apoptosis. 
L. Analyze intracellular igg versus expression for potential that over production may be 
cause lower levels Analysis of transcription and translation mRNA levels 
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APPENDIX 
APPENDIX A  STUDY DESIGN/SAMPLING 
7.1 Apoptosis Analysis - Annexin V/Propidium Iodide 
Apoptosis is a process of programmed cell death, initiated by stimulation of signaling 
cascade.  The monitoring of apoptosis offers a tool in biological discovery process.  One method 
for monitoring apoptosis is the use Annexin V, that can be bound to a fluorescent molecule such 
as fluorescein isothiocyanate (FITC).  This molecule can selectively bind to the cell surface 
protein phosphatidyl-serine.  Phosphatidyl-serine is typically attached to the interior of cell 
membrane.  During apoptosis, prior to the loss of cell membrane integrity, phosphatidyl-serine 
will shift to the extracellular side of the cell membrane.  This process acts as a marker for early 
apoptosis.  Staining with Annexin V is generally combined with a vital dye such as propidium 
iodide (PI) or with 7-Amino-Acintomycin (7-AAD).  PI and 7-AAD are able to stain dead and 
damaged cells because their membrane is permeable.  Cells not staining Annexin V and not for 
PI are considered viable and non-apoptotic, those staining for Annexin V but not PI are 
considered to be early apoptotic, and those staining for both dyes are considered in late apoptosis 
or dead.   Using a combination of these dyes is not able to distinguish between cells that have 
died from apoptosis or necrosis.  However, measuring the cell population over time, one can see 
the progression of the cell population from viable, living cells to early apoptotic cells, to late 
stage apoptosis and death. 
7.2 Staining Protocol 
Wash cells twice with cold PBS and then resuspend cells in 1X Binding Buffer at a concentration 
of 1 x 10^6 cells/ml. 
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Transfer 100 μL of the solution (1 x 10^5 cells) to a 5 ml culture tube. 
Add 5 μL of FITC Annexin V and 5 μL PI. 
Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark. 
Add 400 μL of 1X Binding Buffer to each tube. Analyze by flow cytometry within 1 hr. 
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 APPENDIX B  SUPPLEMENTARY DATA 
Experiment 1  
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Experiment 2  
BA and NAC Protein Production 
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Experiment 2  
PA and NAC Protein Production 
One-way Analysis of Variance (ANOVA) 
PA ICA 
 
PA P 
 
PA qp 
 
 
